| BioLineRx is a late clinical-stage biopharmaceutical development company with a focus on oncology. Co.'s development and commercialization pipeline consists of two clinical-stage therapeutic candidates: motixafortide (BL-8040), a peptide for the treatment of stem cell mobilization, solid tumors and acute myeloid leukemia, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, Co. has a therapeutic product called BL-5010 for the treatment of skin lesions. The BLRX YTD return is shown above.
The YTD Return on the BLRX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether BLRX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BLRX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.